Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Got in a little early. Able to avg down to .68. I can wait for my 50% return.
$heff bought in yesterday. Large float looking for some covering today and a nice bounce. Time will tell.
trlpf any idea why it dropped yesterday, tempted to pick up some more but difficult to find info. Im in at .70
http://www.trimelpharmaceuticals.com/Portals/0/IR%20-%20%20February%202014.pdf
Lxrx bought in last week. Thinking this is bottom with near term catalyst. I'll take 3!
Etrm averaged down myself. Really would love to see $heff buy back in and have it bust through that resistance.
.TRLPF .72 PDUFA date in May. hoping this moves like other Canadian stock NRIFF did leading up to approval.
Trlpf Pdufa
Market Wire
— 7:55 AM ET 01/17/2014
TORONTO, ONTARIO -- (Marketwired) -- 01/17/14 -- Trimel Pharmaceuticals Corporation (TRLPF) today announced that the United States Food and Drug Administration ("FDA") has decided to extend the Prescription Drug User Fee Act (PDUFA) target action date for the CompleoTRT™ new drug application ("NDA") from February 28, 2014 to May 28, 2014. This will provide the FDA with the required time for a full review of the submission in light of the previously announced decision by the Company to amend its proposed label.
"As the FDA considered the change in labelling a major amendment, we understand that this extension is consistent with their normal practices in these circumstances," stated Tom Rossi, President and Chief Executive Officer. "We will continue to work closely with the FDA in order to obtain approval for this important therapy as quickly as possible."
About CompleoTRT™
Trimel's most advanced product candidate, CompleoTRT™, is a bioadhesive intranasal gel formulation of testosterone. CompleoTRT™ is designed with a view to providing hypogonadal patients with superior safety and enhanced convenience over currently available treatment options.
About Trimel
Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. An NDA for CompleoTRT™, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been accepted for review by the FDA for regulatory approval in the United States. For more information, please visit www.trimelpharmaceuticals.com.
Notice regarding forward-looking statements:
Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the Company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the Company is subject to a number of risks and uncertainties, including that CompleoTRT™ may not be approved by the FDA or that any approval may be delayed, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our prospectus dated April 18, 2013 which is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.
.TRLPF .72 PDUFA date in May. hoping this moves like other Canadian stock NRIFF did leading up to approval.
Trlpf Pdufa
Market Wire
— 7:55 AM ET 01/17/2014
TORONTO, ONTARIO -- (Marketwired) -- 01/17/14 -- Trimel Pharmaceuticals Corporation (TRLPF) today announced that the United States Food and Drug Administration ("FDA") has decided to extend the Prescription Drug User Fee Act (PDUFA) target action date for the CompleoTRT™ new drug application ("NDA") from February 28, 2014 to May 28, 2014. This will provide the FDA with the required time for a full review of the submission in light of the previously announced decision by the Company to amend its proposed label.
"As the FDA considered the change in labelling a major amendment, we understand that this extension is consistent with their normal practices in these circumstances," stated Tom Rossi, President and Chief Executive Officer. "We will continue to work closely with the FDA in order to obtain approval for this important therapy as quickly as possible."
About CompleoTRT™
Trimel's most advanced product candidate, CompleoTRT™, is a bioadhesive intranasal gel formulation of testosterone. CompleoTRT™ is designed with a view to providing hypogonadal patients with superior safety and enhanced convenience over currently available treatment options.
About Trimel
Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. An NDA for CompleoTRT™, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been accepted for review by the FDA for regulatory approval in the United States. For more information, please visit www.trimelpharmaceuticals.com.
Notice regarding forward-looking statements:
Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the Company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the Company is subject to a number of risks and uncertainties, including that CompleoTRT™ may not be approved by the FDA or that any approval may be delayed, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our prospectus dated April 18, 2013 which is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.
.TRLPF .72 PDUFA date in May. hoping this moves like other Canadian stock NRIFF did leading up to approval.
Trlpf Pdufa
Market Wire
— 7:55 AM ET 01/17/2014
TORONTO, ONTARIO -- (Marketwired) -- 01/17/14 -- Trimel Pharmaceuticals Corporation (TRLPF) today announced that the United States Food and Drug Administration ("FDA") has decided to extend the Prescription Drug User Fee Act (PDUFA) target action date for the CompleoTRT™ new drug application ("NDA") from February 28, 2014 to May 28, 2014. This will provide the FDA with the required time for a full review of the submission in light of the previously announced decision by the Company to amend its proposed label.
"As the FDA considered the change in labelling a major amendment, we understand that this extension is consistent with their normal practices in these circumstances," stated Tom Rossi, President and Chief Executive Officer. "We will continue to work closely with the FDA in order to obtain approval for this important therapy as quickly as possible."
About CompleoTRT™
Trimel's most advanced product candidate, CompleoTRT™, is a bioadhesive intranasal gel formulation of testosterone. CompleoTRT™ is designed with a view to providing hypogonadal patients with superior safety and enhanced convenience over currently available treatment options.
About Trimel
Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. An NDA for CompleoTRT™, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been accepted for review by the FDA for regulatory approval in the United States. For more information, please visit www.trimelpharmaceuticals.com.
Notice regarding forward-looking statements:
Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the Company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the Company is subject to a number of risks and uncertainties, including that CompleoTRT™ may not be approved by the FDA or that any approval may be delayed, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our prospectus dated April 18, 2013 which is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.
.TRLPF .72 PDUFA date in May. hoping this moves like other Canadian stock NRIFF did leading up to approval.
Trlpf Pdufa
Market Wire
— 7:55 AM ET 01/17/2014
TORONTO, ONTARIO -- (Marketwired) -- 01/17/14 -- Trimel Pharmaceuticals Corporation (TRLPF) today announced that the United States Food and Drug Administration ("FDA") has decided to extend the Prescription Drug User Fee Act (PDUFA) target action date for the CompleoTRT™ new drug application ("NDA") from February 28, 2014 to May 28, 2014. This will provide the FDA with the required time for a full review of the submission in light of the previously announced decision by the Company to amend its proposed label.
"As the FDA considered the change in labelling a major amendment, we understand that this extension is consistent with their normal practices in these circumstances," stated Tom Rossi, President and Chief Executive Officer. "We will continue to work closely with the FDA in order to obtain approval for this important therapy as quickly as possible."
About CompleoTRT™
Trimel's most advanced product candidate, CompleoTRT™, is a bioadhesive intranasal gel formulation of testosterone. CompleoTRT™ is designed with a view to providing hypogonadal patients with superior safety and enhanced convenience over currently available treatment options.
About Trimel
Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. An NDA for CompleoTRT™, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been accepted for review by the FDA for regulatory approval in the United States. For more information, please visit www.trimelpharmaceuticals.com.
Notice regarding forward-looking statements:
Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the Company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the Company is subject to a number of risks and uncertainties, including that CompleoTRT™ may not be approved by the FDA or that any approval may be delayed, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our prospectus dated April 18, 2013 which is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.
Trimel Pharmaceuticals Corporation (TRLPF
Loading...
)
Kenneth G. Howling
Chief Financial Officer
(416) 679-0536
ir@trimelpharmaceuticals.com
www.trimelpharmaceuticals.com
Navb. Pdufa June. Watch for dip this week.
Trlpf Pdufa
Market Wire
— 7:55 AM ET 01/17/2014
TORONTO, ONTARIO -- (Marketwired) -- 01/17/14 -- Trimel Pharmaceuticals Corporation (TRLPF
) today announced that the United States Food and Drug Administration ("FDA") has decided to extend the Prescription Drug User Fee Act (PDUFA) target action date for the CompleoTRT™ new drug application ("NDA") from February 28, 2014 to May 28, 2014. This will provide the FDA with the required time for a full review of the submission in light of the previously announced decision by the Company to amend its proposed label.
"As the FDA considered the change in labelling a major amendment, we understand that this extension is consistent with their normal practices in these circumstances," stated Tom Rossi, President and Chief Executive Officer. "We will continue to work closely with the FDA in order to obtain approval for this important therapy as quickly as possible."
About CompleoTRT™
Trimel's most advanced product candidate, CompleoTRT™, is a bioadhesive intranasal gel formulation of testosterone. CompleoTRT™ is designed with a view to providing hypogonadal patients with superior safety and enhanced convenience over currently available treatment options.
About Trimel
Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. An NDA for CompleoTRT™, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been accepted for review by the FDA for regulatory approval in the United States. For more information, please visit www.trimelpharmaceuticals.com.
Notice regarding forward-looking statements:
Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the Company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the Company is subject to a number of risks and uncertainties, including that CompleoTRT™ may not be approved by the FDA or that any approval may be delayed, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our prospectus dated April 18, 2013 which is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.
Trimel Pharmaceuticals Corporation (TRLPF
Loading...
)
Kenneth G. Howling
Chief Financial Officer
(416) 679-0536
ir@trimelpharmaceuticals.com
www.trimelpharmaceuticals.com
I did we'll on nrif Canadian pdufa play. Will checkmout
I doubt stock will drop below 1.77 on earnings because there will be too much demand for cheap shares leading up to pdufa date in June. With shorts covering it will be 2.50+ by April.
Aezs shelf filing. 250,000,000. Not sure if its worth letting my capitlaln sit here now
Wish I could afford to put more of m y capital here. Gonna be a lot higher come summer. Wonder if there will be an adcom.
Low float this could run easy
http://shortsqueeze.com/?symbol=Cbmx&submit=Short+Quote%99
Earnings cooking up jumped back in my self
I am. Silent follower of this board and I have to thank all for their solid due diligence, morality, and humor. It is great to have the shared goal of making money regardless of where that money is being spent.
definitely a "soft" CRL. Matter of months to clear up.
Astm. Another low float play... Lots of people lost money on this last year but I think could be ready for gains 2014.
Cbmx earnings end of month ready for another run
If no delay by Mid week I think approval in the bag any price above 4 is good. Money to move from vanda to chip and expect move to 5 by mid week. Gonna look to by low 4s Monday if I can.
This OTC no halt usually
$heff bought in today. I do not think a lot of his followers did not get in today. Will move up some more tomorrow hopefully.
Aezs 1.28 May add if it drops more w/ the market on Monday.
Chtp if no delay by end next week watch this start to move. Still think there will be buying opportunity this week.
I think one article had concerns on efficacy after a certain duration so that would be the only label concern? Have to look later. This is gonna be 6 easy b4 pdufa without a delay
If a delay would most likely be due to labeling, but they have been had plenty of time and interaction with company so I do not believe there will be one. The possibility of a delay is what has kept pps stagnant. Rarely is a delay announced less than week or so from pdufa date so I think upward movement will begin next week.
Vnda pdufa date 1-31-14. Do not expect any great gains because approval may b factored in somewhat. Looking to enter low 13's tomorrow and sell high 15's on approval
Igxt- finally gonna break. .74 on to ifs run up to Feb Pfufa date .. will sell most of my shares b4 if not all.
Aezs. - good z to buy in and just let money sit for 9 months ..easy 3 bagger if u don't need the capital.
Missed it at open. See if there is covering
Nice trading...holding mine willsell half at 6
Filled today 3.20. Thinke we will see 6 in February.
Nriff moving into pdufa date next month. Got in late but room to run
I should have gotten in this last month at 1.45 still has room to go up to pdufa
News
$heff bought into this one. News will push this up quickly
Pdufa 2-7 pps 2.04 today will be much higher IMO in next few weeks